➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Harvard Business School
Colorcon
Baxter
Moodys

Last Updated: August 14, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for TAK-071

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug TAK-071?

TAK-071 is an investigational drug.

There have been 332 clinical trials for TAK-071. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2018.

The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).

There are eleven US patents protecting this investigational drug and twenty-four international patents.

Recent Clinical Trials for TAK-071
TitleSponsorPhase
A Study to Evaluate the Safety,Tolerability, and Pharmacokinetics (PK) of TAK-951 in Healthy Participants Following Intravenous AdministrationTakedaPhase 1
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Doses With Titration of TAK-935 in Healthy Japanese ParticipantsTakedaPhase 1
A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in AdultsTakedaPhase 1

See all TAK-071 clinical trials

Clinical Trial Summary for TAK-071

Top disease conditions for TAK-071
Top clinical trial sponsors for TAK-071

See all TAK-071 clinical trials

US Patents for TAK-071

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
TAK-071   Start Trial Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
TAK-071   Start Trial Nitrogen-containing heterocyclic compound Takeda Pharmaceutical Company, Limited (Osaka, JP)   Start Trial
TAK-071   Start Trial Nitrogen-containing heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Harvard Business School
Colorcon
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.